logo
Validation: Here's How These Skills Can Transform Your Relationships

Validation: Here's How These Skills Can Transform Your Relationships

Forbes26-05-2025

Psychologist, author and adjunct instructor at Stanford University Caroline Fleck, PhD, has a new ... More book out entitled Validation: How the Skill Set That Revolutionized Psychology Will Transform Your Relationships, Increase Your Influence, and Change Your Life. (Photo: Courtesy of Caroline Fleck, PhD)
In trying to connect with or even influence someone, you may be making a valid point. Or multiple valid points. But maybe you should consider making validation a point as well. This is what Caroline Fleck, PhD, essentially recommends in her new book entitled Validation: How the Skill Set That Revolutionized Psychology Will Transform Your Relationships, Increase Your Influence, and Change Your Life. And what follows after the word 'validation' in the title is a spoiler alert as to what she feels providing validation to others can do.
'The impetus for writing the book was a kind of light bulb moment in my experiences over the years as a clinician,' Fleck recalled to me during a recent conversation. She is a cognitive behavioral psychologist and an adjunct clinical instructor at Stanford University. Her private practice specializes in using dialectical behavior therapy and other cognitive behavioral approaches to treat different mood, anxiety, and personality disorders. 'Dialectical behavior therapy was the first evidence-based treatment for borderline personality disorder,' Fleck went on to say. 'It did this really wild thing back in the 90s. It combined this emphasis on acceptance with change.'
She clarified why this approach was so 'wild' at the time: 'The thing you need to change in BPD most immediately is typically self-harm and suicidal behavior and so the stakes are really high in these cases and they found that standard behaviorism, you know reinforcement, shaping habits, all of the popular concepts that were out there, none of that was working in this population. They were considered untreatable.'
But here's how DBT was wildly different in Fleck's words: 'It wasn't until we incorporated validation and had this corresponding emphasis on communicating acceptance that we were able to facilitate change. And all of a sudden we had an evidence-based treatment for a condition that had been considered untreatable.' The light bulb moment for Fleck was when both her professional and personal experiences showed her what validation can do. 'I think we've really limited it, we've only looked at in these extreme cases,' she emphasized. 'When you start incorporating validation in professional contexts, in parenting or in marital relationships, the change you see is remarkable.'
Now, to understand how validation might work, you have to understand what validation is and isn't. Fleck defines validation as communicating mindfulness, understanding, and empathy in ways that convey acceptance. She has used the mantra, 'Validation shows that you're there, you get it, and you care,' to clarify what this means. In other words, by providing validation, you are telling the other person that you respect him or her enough to realize that there's reasoning and a rationale explanation involved.
The opposite of validation would be dismissal, judgement or trying to fix the person. Classic non-validating responses would be like 'Here's where you are wrong', 'Here's what you should do instead' or simply 'You are freaking nuts.' You would be essentially quickly saying what the person is thinking, saying or doing is wrong, wrong, wrong like a bathroom gong. And how many people would say, 'Please tell me how stupid I am' or 'Please tell me how I screwed up again?'
Note that this definition of validation doesn't imply agreement or even praise of what the other person is thinking. So validation wouldn't require saying something like, 'Good on you that you think the world is flat' or 'Yes, I agree with you. Nicholas Cage is indeed a vampire.' It's more about that you have a genuine interest in understanding how the person got to where he or she is.
Fleck has emphasized how transformative validation can be for any kind of relationship—including your relationship with yourself. In fact, she likened it to 'MDMA for your relationships' in the Next Big Idea Club, not that you necessarily should be taking MDMA for any of your relationships. She spoke of how validation can provide more trust, intimacy and psychological safety and how research studies has revealed that the presence versus absence validation can help predict whether a relationship will be successful or not.
'There's many people who simply want to be heard or see," Fleck said. 'But that doesn't seem to be acknowledged enough in our society.' Providing validation can be particularly useful during a conflict. Fleck analogized it to putting up an adorable cat filter during a video meeting. It can be less threatening and disarming—that's assuming that you don't believe that your cat is plotting to kill you as I've written about previously. And when a person feels more comfortable with you, more in the 'oh he or she gets me" state of mind and less in the alarm state, that person may be more likley to listen and open to discussion.
So, it's simple, right? Everyone should provide each other with more validation and presto, chango, bingo, no more conflict, no more relationship problems, right? Not exactly. Providing validation can be easier said than done. First of all, a big part of validation is withholding judgement. This isn't always easy to do since it's oh so easy to judge others just like it's easier to sit in the America's Got Talent judging chairs than perform on stage. Being all judgy can make you feel superior and better about yourself.
Fleck pointed out another problem, 'We are a problem solving culture. We are not really trained in how to sit with emotion when someone comes to us with a problem. Our inclination is to problem solve. And we are good at it.' So, in other words, one problem is too much problem solving. She spoke of 'how we're not great at just accepting and being with difficult emotions that another person might be experiencing,' and gave an example of 'like when my kid doesn't do well on a spelling quiz,. My inclination is to immediately problem solve what can they do better next time, so that this doesn't happen again.'
Fleck described how this affects a second issue or obstacle. 'We don't really teach kids to validate their own emotions to recognize, hey, I'm disappointed, I'm sad, I'm frustrated,' she said. 'Instead, what we model, what we show them to do, is immediately work towards change.' Fleck added that through all her work, 'I have yet to meet anyone who was really great and self validation. who could really recognize their emotions, see the validity in them, sit with them, and then regulate effectively. Instead what I see are folks who are very punitive towards themselves, self critical, and quick to try and problem solve and change change change, whatever is what 'wrong with them.''
An additional issue is that validation doesn't work if it is fake. In order words, the actual validation part has to be, you know, valid. 'Anything that is fake is not validation,' Fleck emphasized. 'I need to really underline that because folks think they can salesman their way into this, you know, like just say whatever they want. But guess what, people see through that.' Case in point, I've written for Psychology Today about how I once told a workplace leader, 'I don't feel like you heard me' and received the rather invalidating response of, 'I hear you, man,' followed by his promptly leaving before I had any opportunity to fully elaborate. Therefore, you've got to want to hear the other person out honestly and earnestly. Otherwise, it's going to come off as the opposite. And being real and authentic in our salesy, fake it until you make it society isn't always easy to do.
So, how do you authentically validate what someone is saying and doing when you are like 'Holy moly what the heck is this person saying and doing?' Fleck suggested first finding that kernel of truth in what the other person is saying or doing. Because there's almost always some truth behind anything. People are rarely completely wrong and completely irrational. Fleck has pointed out that someone's behavior and emotions may be valid even though what led to them were not, and vice versa. She's also emphasized how emotions are always valid. If you feel sad about something, for example, someone else can't say, 'No you don't. You don't feel sad.' It's not like you will turn around and respond, 'That's right. I actually feel happy. Thank you for clarifying that for me.'
Say someone voted for a political candidate whom you find highly distasteful or didn't vote in a crucial election. It will probably wont' get anywhere by calling that person a complete idiot or completely fooled. However, you could make inroads trying to see what made sense in that person's choice. Maybe that person has a major distrust of politicians in general—which wouldn't be unreasonable. That distrust could have led to the person eschewing voting or voting for the 'non-traditional' candidate. The kernel of truth could then be the distrust or dislike of politicians.
Fleck has described a ladder of validation with progressively higher skill levels that people can ... More climb to like rungs on a ladder. (Photo: Getty)
Validation is like any skill, though. It may come more naturally to some who may naturally be more empathic and better communicators compared to others may struggle more. But no one should assume that they are just born to do it and can provide validation relatively easily without working to hone the skill. For example, some folks may describe themselves as highly sensitive empaths but that doesn't necessarily mean that they are good at validation. 'What the highly sensitive empaths don't always realize is that although they can sense certain emotions, that doesn't mean that they can communicate that understanding effectively,' said Fleck. 'They haven't actually developed skills to help them get better at it because they haven't seen the need to. They feel like they have this natural talent so they don't have to work it.' The analogy would be the basketball player who can outjump everyone but doesn't feel like he or she has to practice the jump shot, dribbling, rebounding and other stuff.
Fleck has described a ladder of validation with progressively higher skill levels that people can climb to like rungs on a ladder. The higher you can get on this ladder, the greater connection with others you can achieve. But don't despair if you can only climb so high. Not everyone can be a Michael Jordan of validation. The key is to be on the ladder in the first place and work to get as high as you can.
Before you do anything, you've got to pay attention and listen to what the other person is saying. Like really listen. So the first two rungs on the validation are about mindfulness: attending and copying. Attending is offering all the cues, verbal and non-verbal, that you are offering your full attention. This should maintaining eye contact, nodding when appropriate (as opposed to nodding like a bobblehead or nodding off), asking appropriate questions and showing the proper facial expressions. For example, don't look like The Joker about to blow up Gotham City when the person is expressing hardships being faced. While attending, you want to really figure out what the person is saying and what's behind it all.
The second rung is copying, another name for mirroring. When you repeat what the other person says or does like body positioning, they other person can feel like you are both on the same page and you understand. Naturally, this has to be appropriate. When the other person says, 'I feel really stupid,' appropriate mirroring would not be, 'yeah, you are really stupid.' Instead, it would be more, 'Yeah, I feel stupid in such situations too.'
Once you're able to listen and mirror, your ready to really understand what the person is saying and doing. The first of these understanding rungs is called equalizing. This where you acknowledge that what the person is feeling and thinking make sense given that person's circumstances. Again, it's not necessarily agreement or praise. But it's making it clear that you don't feel that they are way off base.
The second rung in this group and fourth overall is contextualizing. This is where you understand how that person's thoughts and behavior fit in the broader context of things. For example, maybe the person said or did something not so nice because he or she was stressed or afraid.
The third rung in this group and fifth overall is where things get particularly tricky. Its dubbed proposing and doesn't mean you propose marriage to the other person, which would be weird. It's where you guess what the other person is thinking or feeling. Now be careful with this one. It can work well and further your connection with each other if you are spot on but do the opposite if you get it wrong. If you elicit a 'yeah, you don't really know me' or 'who the bleep do you think you are' or 'I'm not that simple,' apologize and accept the fact that you've fallen down a few rungs on the ladder, at least with this person.
Once you've mastered the levels of understanding, you may be ready for the empathy rungs of the ladder. This starts with the sixth overall rung: emoting. This is where you express your own emotions that are genuine and appropriate reactions to what you've seen and heard. An example is the significant other who got teary eyed when I told her of my brother's death years prior. Another example is when someone gets visibly excited when something good happens in your life.
The seventh overall rung and second in the empathy group is taking action. This is where you do something concrete to help the other person. So, if the other person's is feeling lonely, maybe you help that person find a partner. Of course, it's better to get that person's permission first. You don't want to say after the fact, 'Hey I signed you up for Tinder and included all your personal details om your profile. By the way, you've got a date with someone who was carrying a really big fish in a profile pic.'
The final tippy top rung is disclosure. This is where you share something that's happened to you that's similar and shows that you can relate. For example, if that person is struggling with a medical condition, maybe you share your own health struggles, which can not only show empathy but maybe even provide valuable insights, as I have described in Forbes previously.
Beware of making this all about you or a competition. You never want to be like 'The discrimination I faced was worse than the discrimination you faced,' because you don't bleeping know and this ain't the freaking Olympics of suckiness. Also, never assume that your experience was identical. Things can be quite different for different people even though the circumstances may appear to be the same.
No matter where your skills may fall on this validation ladder, it's better to rung with it, so to speak, when interacting with anyone else. 'Validation is acceptance,' Fleck emphasized. 'It's being seen and heard. We all need external validation. Our relationships should be based on validation.' And these are all quite valid points.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A woman's heart suddenly stopped. Two passing nurses saved her life.
A woman's heart suddenly stopped. Two passing nurses saved her life.

CBS News

time2 hours ago

  • CBS News

A woman's heart suddenly stopped. Two passing nurses saved her life.

Merryl Hoffman knew she was taking good care of her heart. The 63-year-old attorney didn't smoke or drink, and she was an avid hiker who used to run marathons and other distance races. In her 40s, she had been diagnosed with a leaky mitral valve and underwent surgery to repair it. Every year since, she has seen a cardiologist to check her heart and its function. The reports always came back clear. When Hoffman left her apartment on Manhattan's Upper East Side on Oct. 23, 2025, her heart was the last thing on her mind. She was saddled with her work bag and purse, hightailing it to the subway station so she could make it to work on time. That's when her memory of the day ends. Shortly into her walk, Hoffman experienced a sudden cardiac arrest. Her heart stopped beating. She collapsed to the ground. Doctors later told her it was a severe arrhythmia that could have been fatal — if not for where Hoffman fell. Hoffman had collapsed outside Memorial Sloan Kettering Cancer Center's Breast and Imaging Center, about two and a half blocks from her subway station. A patient care technician and a passing runner immediately rushed to her aid. Then, Memorial Sloan Kettering nurses Sabrina Castle and Gianna Formisano stumbled upon the scene while walking to work. "We were so shocked. When we were walking up, people were like 'Nurses, nurses!' We didn't know what we were walking into," Formisano said. "People were grabbing our coffee, taking our bags. It was out of a movie, the way that they were like 'Oh, thank God you're here.'" Sabrina Castle and Gianna Formisano outside the Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering "They absolutely saved my life" Formisano and Castle took over performing CPR, keeping Hoffman's heart manually beating. She didn't have a pulse, and she had hit her head when she collapsed. The nurses also instructed one of the other bystanders to call an ambulance. Early CPR increases survival for patients in cardiac arrest by "at least two or three fold," said Dr. Jessica Hennessey, a cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center. Early CPR means that blood flow to the brain and heart continues, preserving the health of those organs. Bystanders in a medical emergency should call 911 and immediately start CPR, Hennessey advised. CPR can be done with mouth-to-mouth or with just chest compressions, Hennessey said. After five minutes that "felt like forever," the ambulance arrived, Formisano said. Castle and Formisano helped the EMTs load Hoffman into the ambulance. Then, she was taken to NewYork-Presbyterian's cardiac care unit for further treatment. For the small crowd, the day carried on. Castle and Formisano headed to work. After a few hours, they called NewYork-Presbyterian to see if they could find out more about Hoffman's status. They went to the hospital and spoke to a nurse there. "She was like, 'You got her back. She's intubated, she's alive, you saved her life,'" Castle recalled. Hoffman was still unconscious. She told CBS News that she didn't wake up until five days after the collapse. Her family told her that she had been rushed into surgery. Doctors told her that her heart had stopped for several minutes -- and the actions of Castle, Formisano and other bystanders had saved her. "Without them, I was told, there was no doubt I would have died or been brain dead," Hoffman said. "They absolutely saved my life." Hoffman had an implantable cardioverter-defibrillator placed in her chest to prevent further cardiac arrests. The device shocks the heart if it detects an irregular heartbeat. She also began cardiac rehabilitation. Shortly after, she returned to work. Life began to get back to normal but one question was constantly at the back of her mind: Who had helped save her? A chance reunion While in cardiac rehabilitation, Hoffman found herself telling the story of the strangers who had helped her. A physiologist there overheard her talking about it and thought the story sounded familiar. His girlfriend was friends with two nurses who had helped a woman matching Hoffman's description. After some back and forth, the physiologist connected Hoffman with Castle and Formisano. The trio immediately made plans to get dinner. Hoffman's husband joined them for the meal. There, the nurses were able to fill in the gaps of the October morning when Hoffman collapsed. Sabrina Castle, Merryl Hoffman and Gianna Formisano at the site where Hoffman collapsed. Sabrina Castle and Gianna Formisano "It was very jarring, when they gave my husband and I the blow-by-blow of that morning. There were things we did not know," Hoffman said. "It was pretty incredible." Since that dinner, the women have stayed in touch. Recently, Castle and Formisano even passed Hoffman on the same block where she had collapsed. The three took a photo at the site. "We were like, 'Wow, this is really crazy,'" Formisano said. "'We're running into you on the same spot, on your way to work, on our way to work, but now you're alive and well and in a much different state than when we met you the first time.'"

Psychedelics as potential mental health treatment are explored by Trump administration
Psychedelics as potential mental health treatment are explored by Trump administration

Yahoo

time2 hours ago

  • Yahoo

Psychedelics as potential mental health treatment are explored by Trump administration

The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Yahoo

time2 hours ago

  • Yahoo

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value 0.005, HR: 0.46 [0.26, 0.80]) observed in 3rd-6th line metastatic pancreatic cancer, correlated with reversal of lymphopenia. Patients with lower tumor burden and improved lymphocyte counts (ALC ≥1,000) had a median overall survival of 10.1 months, supporting earlier intervention in the disease course. CULVER CITY, Calif., June 03, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While anemia and neutropenia have long been addressed by agents like Epogen and Neupogen, no therapy has ever existed for lymphopenia—until now. ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist approved in April 2024 for BCG-unresponsive non-muscle- invasive bladder cancer carcinoma in situ with or without papillary disease, represents the first lymphocyte-stimulating agent (LSA) capable of expanding lymphocytes critical for immunogenic cell death, such as natural killer (NK) and T cells. These findings emphasize the need for a therapy to overcome treatment induced lymphopenia with higher mortality as presented at ASCO 2025 by several institutions (Abstract #8054, Satoskar et al. and Abstract #2663, Saleh et al.) In a single-arm QUILT-88 clinical trial of 86 participants with third-to-sixth-line metastatic pancreatic cancer with very high tumor burden (CA19-9 levels exceeding 34,000 IU/ml), for which no therapy currently exists, patients received ANKTIVA subcutaneously in combination with off-the-shelf, ex-vivo infusion of CAR-NK cells (PD-L1 t-haNK) and low dose immuno-modulating chemotherapy. This first reported study of treating lymphopenia demonstrated significant differences in median overall survival in subjects whose lymphopenia was reversed (Absolute Lymphocyte Count: ALC ≥ 1,000). In 67 out of 86 subjects, reversal of lymphopenia was achieved and median overall survival was significantly prolonged compared to those who remained in severe lymphopenia with P-value 0.005, HR: 0.46 (0.26, 0.80) in Figure 1. In subjects with lymphopenia rescue and a lower tumor burden (less than the median CA19-9 of 34,000 IU/mL), the median overall survival in these very advanced metastatic pancreatic cancer patients exceeded 10 months (Figure 2). These findings of improved survival in pancreatic cancer patients with lower tumor burden point to the potential of further prolonged overall survival in pancreatic cancer patients if treated in the first line or neoadjuvant stages of disease. Highlighting the importance of lymphopenia reversal, Oncologist published a peer-reviewed paper titled "Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate," demonstrating that in a patient with 2nd line metastatic pancreatic cancer treated with the full Cancer BioShield platform—including ANKTIVA, CAR-NK cells (PD-L1 t-haNK), and antigen-targeting adenoviruses—remained in remission for over six years and maintains a high quality of life at the date of this release. The expanded access authorization announced yesterday enables patients across all solid tumor types who have exhausted first-line therapy including chemotherapy, radiation, or immunotherapy to receive Anktiva as a lymphocyte stimulating agent to protect the immune system from the lymphogenic adverse effects of current standards of care. The ASCO Annual Meeting 2025 materials from ImmunityBio can be found below: Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic Text: Poster PDF: About the Cancer BioShield™ Platform The Cancer BioShield platform is a first-in-class immunotherapy strategy designed to restore immune competence by reversing lymphopenia—the loss of functional immune cells caused by cancer itself and by conventional treatments such as chemotherapy, radiation and immunotherapy. At its core is ANKTIVA® (nogapendekin alfa inbakicept-pmln), an IL-15 agonist approved for BCG-unresponsive non-muscle-invasive bladder cancer CIS with or without papillary disease, activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells, restoring lymphocyte levels critical for immunosurveillance, immunogenic cell death, and long-term tumor control. The platform employs a multi-modal approach: In-vivo stimulation: Subcutaneous administration of ANKTIVA expands NK and T cells, boosting anti-tumor immunity. Ex-vivo targeted cytotoxicity: Off-the-shelf PD-L1 t-haNK CAR-NK cells are engineered to target and eliminate PD-L1–expressing tumor cells and immunosuppressive neutrophils (myeloid-derived suppressor cells), enhancing anti-tumor specificity and reducing immune evasion. Memory Cytokine-Enriched Natural Killer (M-ceNK) cell therapy: M-ceNK cells are developed via cytokine activation and expansion of autologous and allogeneic NK cells collected through apheresis, potentially providing long-term immune memory and sustained cytotoxic capacity. Together, these components offer a comprehensive, novel, immune-restoring therapeutic platform aimed at not only expanding effector immune cells but also overcoming tumor-mediated immune suppression to support long-term disease control. The platform's effectiveness can be tracked through universally utilized, simple complete blood count (CBC): increases in absolute lymphocyte count (ALC) reflect ANKTIVA's lymphocyte-stimulating activity, while reductions in the neutrophil-to-lymphocyte ratio (NLR) demonstrate PD-L1 t-haNK's immunosuppressive neutrophil targeting. Low ALC and high NLR levels are laboratory measurements that have been extensively reported as predictive biomarkers of poor prognosis with early mortality across all tumor types5,6. The data presented by ImmunityBio for the first time demonstrates that improving ALC and NLR correlates with significant enhanced overall survival and clinical benefit. About Lymphopenia and Absolute Lymphocyte Count (ALC) Lymphopenia—the loss of key immune cells such as NK, CD4+, and CD8+ T cells—is a common side effect of chemotherapy1, radiation2,3, and some immunotherapies4. Unlike anemia and neutropenia, which have FDA-approved treatments like EPO and Neupogen, no therapy previously existed to treat this immune cell depletion. Lymphopenia weakens the immune system, increases infection risk, and is linked to early death across many cancer types5. Low Absolute Lymphocyte Count (ALC) is a recognized poor prognostic marker. ANKTIVA® is the first approved therapy to restore lymphocyte levels by activating and expanding NK and T cells—without increasing immunosuppressive T regulatory cells7. More information on lymphopenia could be found on Twitter/X @DrPatSoonShiong articles here: References: Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/ Epub 2009 Jun 23. PMID: 19549917; PMCID: PMC2775079. Chen D, et al. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):196-203. doi: 10.1016/ Epub 2020 Feb 7. Pike LRG, et al. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151. doi: 10.1016/ Epub 2018 Sep 15. PMID: 30227198. Lee, Y.J., et al. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep 12, 626 (2022). Ménétrier-Caux C., et al. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? J Immunother Cancer. 2019 Mar 28;7(1):85. doi: 10.1186/s40425-019-0549-5. PMID: 30922400; PMCID: PMC6437964. Templeton AJ, et al. Prognostic role of neutrophil-to-lymphocyte (NLR) ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi: 10.1093/jnci/dju124. PMID: 24875653. FDA ANKTIVA Label, April 2024 - About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the expectation that the EAP described herein will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iii) risks and uncertainties regarding commercial launch execution, success and timing, (iv) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (v) whether clinical trials will result in registrational pathways and the risks, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) ImmunityBio's ability to retain and hire key personnel, (x) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xi) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store